公开(公告)号：US20210317068A1

公开(公告)日：2021-10-14

申请号：US17348985

申请日：2021-06-16

申请人： OHIO UNIVERSITY

发明人： XIAOZHUO CHEN ,  STEPHEN BERGMEIER

IPC分类号： C07C205/32 ,  C07C211/48 ,  C07C39/367 ,  C07C43/23 ,  C07C235/56 ,  C07D209/08 ,  C07D231/12 ,  C07D233/64 ,  C07D235/18 ,  C07D249/08 ,  C07D319/20 ,  A61K31/09 ,  A61K45/06 ,  C07C43/253 ,  C07D311/16 ,  C07D311/82

摘要： Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.

公开(公告)号：US20210261723A9

公开(公告)日：2021-08-26

申请号：US16063673

申请日：2016-12-16

申请人： Cambridge Display Technology Limited ,  Sumitomo Chemical Company Limited

发明人： Thomas Kugler ,  Sheena Zuberi ,  Florence Bourcet

IPC分类号： C08G61/02 ,  C07D235/18 ,  H01L51/00

摘要： A charge-transfer salt formed from a material comprising a repeat unit of formula (I) and an n-dopant: wherein BG is a backbone group of the repeat unit; R1 is a ionic substituent comprising at least one cationic or anionic group; n is at least 1; R2 is a non-ionic substituent; and m is 0 or a positive integer; the material further comprising a counterion balancing the charge of the cationic or anionic group.

公开(公告)号：US11028073B2

公开(公告)日：2021-06-08

申请号：US16478400

申请日：2018-01-04

申请人： GUANGDONG LONGFU MEDICINE CO., LTD.

发明人： Zhangjian Huang ,  Tao Pang ,  Cunfang Wang ,  Wenbin Zeng ,  Jinxiang Deng ,  Weijie Wu ,  Tingyu Huang

IPC分类号： C07D235/18 ,  C07D257/04 ,  C07D403/10 ,  C07D403/04 ,  A61P9/10 ,  A61P25/16 ,  A61P29/00

摘要： The invention discloses a butylphthalide-telmisartan heterocomplex, a preparation method and an application thereof. The invention specifically relates to an optically active ring-opening butylphthalide-telmisartan heterocomplex shown in formula I or a pharmaceutically acceptable salt or ester thereof, a preparation method thereof, a pharmaceutical composition containing the compounds, and a pharmaceutical application thereof, particularly application in prevention and treatment of neuroinflammation-related diseases, including ischemic stroke, Alzheimer's disease, brain trauma, Parkinson's disease, multiple sclerosis, depression and so on.

公开(公告)号：US20210059985A1

公开(公告)日：2021-03-04

申请号：US16844414

申请日：2020-04-09

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： Khoa Dinh NGUYEN ,  Edgar G. ENGLEMAN

IPC分类号： A61K31/404 ,  A61K31/4184 ,  C07D235/18 ,  A61P25/00 ,  A61P29/00 ,  A61K9/00

摘要： The present invention is directed to a method for preventing and/or treating aging-related cognitive impairment in the central nervous system. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

公开(公告)号：US10892419B2

公开(公告)日：2021-01-12

申请号：US16158087

申请日：2018-10-11

申请人： LG Display Co., Ltd.

发明人： Hyo-Jin Noh ,  Kyung-Jin Yoon ,  Dae-Wi Yoon ,  In-Ae Shin ,  Jun-Yun Kim

IPC分类号： H01L51/00 ,  C07D403/10 ,  C09K11/06 ,  C07D213/38 ,  C07D235/18 ,  H01L27/32 ,  C09K11/02 ,  H01L51/50 ,  C07D401/10

摘要： Discussed is a space-through charge transfer compound including a naphthalene core; an electron donor moiety selected from carbazole and phenylcarbazole; and an electron acceptor moiety selected from pyridine, diazine, triazole, and phenyl benzodiazole, wherein the electron donor moiety and the electron acceptor moiety are combined to first and eighth positions of the naphthalene core with a benzene linker, respectively.

公开(公告)号：US10797245B2

公开(公告)日：2020-10-06

申请号：US15517622

申请日：2015-11-20

申请人： SAMSUNG SDI CO., LTD.

发明人： Hyung Sun Kim ,  Byungku Kim ,  Youngkwon Kim ,  Younhwan Kim ,  Hun Kim ,  Eun Sun Yu ,  Sung-Hyun Jung

IPC分类号： H01L51/54 ,  C09K11/06 ,  H01L51/00 ,  H01L51/50 ,  H05B33/20 ,  C07D233/58 ,  C07D235/18 ,  C07D239/26 ,  C07D239/70 ,  C07D239/74 ,  C07D249/08 ,  C07D251/24 ,  C07D271/107 ,  C07D285/12 ,  C07D401/10 ,  C07D401/14 ,  C09K11/02 ,  H01L51/52

摘要： The present invention relates to a compound for an organic optoelectronic element, represented by chemical formula I, an organic optoelectronic element employing the same, and a display device. The details of chemical formula I above are defined as in the specification.

公开(公告)号：US20200270394A1

公开(公告)日：2020-08-27

申请号：US16063673

申请日：2016-12-16

申请人： Thomas Kugler

发明人： Thomas Kugler

IPC分类号： C08G61/02 ,  C07D235/18 ,  H01L51/00

摘要： A charge-transfer salt formed from a material comprising a repeat unit of formula (I) and an n-dopant: wherein BG is a backbone group of the repeat unit; R1 is a ionic substituent comprising at least one cationic or anionic group; n is at least 1; R2 is a non-ionic substituent; and m is 0 or a positive integer; the material further comprising a counterion balancing the charge of the cationic or anionic group.

公开(公告)号：US10676468B2

公开(公告)日：2020-06-09

申请号：US14415293

申请日：2013-07-19

申请人： IMPACT Therapeutics, Inc.

发明人： Suixiong Cai ,  Ye Edward Tian ,  Sishun Kang ,  Zheng Meng ,  Chengyun Gu ,  Feng Yin ,  Shengzhi Chen ,  Yang Zhang ,  Xiuyan Zhang ,  Hongqiang Fei ,  Dongmei Wang

IPC分类号： C07D413/14 ,  C07D401/10 ,  C07D235/18 ,  C07D403/10 ,  C07D413/10 ,  C07D409/04 ,  C07D401/04 ,  C07D487/04 ,  C07D409/12 ,  C07D401/14 ,  C07D401/12 ,  C07D471/04 ,  C07D233/64 ,  C07D213/40 ,  C07D403/12 ,  C07D413/12 ,  C07D405/12 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/536 ,  A61K31/5377 ,  A61K45/06

摘要： Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.

公开(公告)号：US10651411B2

公开(公告)日：2020-05-12

申请号：US15568116

申请日：2016-09-09

申请人： LG Chem, Ltd.

发明人： Yongbum Cha ,  Jin Joo Kim ,  Seong So Kim ,  Jemin Ryu

IPC分类号： H01L51/50 ,  C09K11/06 ,  C07C13/72 ,  C07C13/567 ,  C07F7/08 ,  C07F9/53 ,  C07C25/22 ,  C07C211/61 ,  C07F5/02 ,  C07D251/24 ,  C07D235/18 ,  C07D333/76 ,  C07D307/91 ,  C07D209/86 ,  C07D213/16 ,  C07D239/74 ,  C07C255/58 ,  C07C211/54 ,  C07D239/26

摘要： The present specification relates to a novel compound and an organic light emitting device including the same.

公开(公告)号：US10512634B2

公开(公告)日：2019-12-24

申请号：US15573439

申请日：2015-05-11

申请人： KANCERA AB

发明人： Johan Schultz ,  Jan Vågberg ,  Elisabeth Olsson ,  Katarina Färnegårdh ,  Mattias Jönsson ,  Kristin Hammer ,  Lars Krüger

IPC分类号： C07D235/18 ,  A61K31/4184 ,  C07D403/04 ,  C07D405/04 ,  A61P37/00 ,  A61P25/00 ,  A61P35/00

摘要： A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.